|
Friday 21st January 2022 |
Text too small? |
In November 2021, ArborGen Holdings Limited (NZX: ARB ) (the Company) announced guidance of US GAAP EBITDA in the range of US$11.3 to $11.7 million for the fiscal year ending 31 March 2022 (FY22) subject to any future impact from supply chain and COVID related issues in the US. Since then the pandemic, including the recent emergence of Omicron, is continuing to cause significant disruptions in the industry ranging from transportation issues to labour shortages.
Accordingly the Company has re-estimated guidance of US GAAP EBITDA to be in the range of US$9.5 to US$10.5 million assuming a certain level of seedlings remain unsold. Almost all of this reduction in EBITDA is from a shortfall in sales of lower margin Open Pollinated (OP) seedlings.
The Company is pleased to confirm that it continues to be on track to deliver its highest Mass Control Pollinated (MCP) sales year in the US this year, with orders tracking 30+% higher than the fiscal year ending March 2021.
Please see the link below for details
ArborGen Holdings Updates Market on FY22 Guidance
Source: ArborGen Holdings Limited
No comments yet
CHI - Channel Infrastructure delivers solid FY25 financial result
February 27th Morning Report
TRU - Results Guidance FY2026
TRU - Results Guidance FY2026
MEE - Me Today announces six-month results to 31 December 2025
HGH - Heartland announces 1H2026 result
BRW - FY26 Half Year Results Announcement
February 25th Morning Report
Genesis completes NZ$100m Placement
MCY - Invests heavily in renewables; delivers strong performance